Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
Betty B YaoLinda M FredrickGretja SchnellKris V KowdleyPaul Y KwoFred PoordadKinh NguyenSamuel S LeeChristophe GeorgeFlorence S H WongEdward J GaneArmand AbergelCatherine W SpearmanTuan NguyenManh Hung LeThuy Tt PhamFederico MensaAsselah TarikPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
This integrated dataset demonstrates a high SVR12 rate following 8-week G/P treatment in patients with HCV GT5 (96%) or GT6 (99%) infection without cirrhosis or with compensated cirrhosis.